← Back

Heart Test Laboratories Inc. Common Stock

HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic ECG management platform. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.

Price · split & dividend adjusted
News & notes moving HSCS
HSCS▲

HeartSciences Files Fiscal 2026 Annual Report on Form 10-K

HeartSciences has filed its Annual Report on Form 10-K for the fiscal year ended April 30, 2026 with the U.S. Securities and Exchange Commission. The company also expects to file shortly a preliminary proxy statement related to its proposed business combination with Fortitude Mining Holdings, a wholly-owned subsidiary of Digital Currency Group. HeartSciences believes the proposed transaction offers a significant opportunity for shareholders, providing continued ownership in a scaled, revenue-generating business while allowing its MyoVista Insights AI-ECG technology to advance with greater focus. Following the proxy filing, the company intends to issue its fiscal 2026 earnings release and a business update, currently expected early next week. CEO Andrew Simpson called fiscal 2026 a landmark year with the launch of MyoVista Insights and the beginning of a transition to mainstream commercial revenue.
HSCS ▲
GlobeNewswire·34dRead more ▾
Biotech & Genomic Medicine

NeOnc, Boundless Bio, Backblaze, and HeartSciences announce major catalysts

Several emerging companies are approaching significant inflection points. NeOnc Technologies received Investigational New Drug authorization from the Department of Health–Abu Dhabi for its NEO100 program, covering adult Phase 1 through Phase 2 studies and establishing a pathway for pediatric development in high-grade gliomas, with a Phase 2a readout expected by the end of July 2026. Boundless Bio announced a proposed merger with privately held Serapha Bio, creating a publicly traded company focused on gene-editing therapies for Alpha-1 Antitrypsin Deficiency, backed by approximately $230 million in committed financing from a syndicate led by RTW Investments and RA Capital Management. Backblaze signed a five-year, multi-exabyte data storage agreement valued at approximately $335 million with AI cloud infrastructure provider CoreWeave, positioning Backblaze as a key storage provider for portions of CoreWeave's managed storage infrastructure. HeartSciences announced a proposed business combination with Fortitude Mining Holdings, a digital asset mining platform focused primarily on Zcash, with existing Fortitude owner Digital Currency Group expected to hold approximately 95% of the combined company upon closing.
BLZE ▲BOLD ▲HSCS NTHI ▲
Biotech & Genomic Medicine ▲Artificial Intelligence ▲
GlobeNewswire·64dRead more ▾
© 2026 MarketDXAsset